REC Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Recordati Industria Chimica e Farmaceutica (BIT: REC)
›
Recordati Industria Chimica e Farmaceutica (BIT: REC) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 4,700 employees.
The shares were at 52.75 EUR on 19 November 2026, up 2.2% over 52 weeks. Its 52-week range is 43.76 EUR to 53.70 EUR: the price is 1.8% below the high and 20.5% above the low.
At a market capitalisation of 10.98B EUR, it trades at 21.0 times trailing earnings and 13.9 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 19% for REC. It pays a dividend yielding 2.69% (it pays out 53% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
Recordati Industria Chimica e Farmaceutica reports return on equity of 23.1%, an operating margin of 32.6% and revenue up 9.6% year over year.
Its debt exceeds its cash by 1.70B EUR, a debt-to-equity ratio of 1.29. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Hold; their mean price target of 56.83 EUR is 7.7% above the current price. The next earnings report is expected on 18 March 2027.